Biopharma Daily Stock Updates - 01/04/21

Updated: Jan 13

$XBI $140.95 (+0.12%) 📈


COVID:

$ARCT (+12.72%) - Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States

https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-receives-fda-allowance-proceed-phase-2


$MRNA (+6.95%) - Moderna Provides COVID-19 Vaccine Supply Update

https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-covid-19-vaccine-supply-update


PIPELINE:

$AYLA (+2.36%) - Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study

https://ir.ayalapharma.com/news-releases/news-release-details/ayala-pharmaceuticals-accelerate-development-al102-treatment


$CALA (-44.60%) - Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint

https://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-reports-cantata-study-telaglenastat-renal


$ENDP (+4.18%) - Endo Launches Authorized Generic Version of Amitiza® (lubiprostone) Capsules in the United States

https://investor.endo.com/news-releases/news-release-details/endo-launches-authorized-generic-version-amitizar-lubiprostone


$PAND (+47.74%) - Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells

https://investors.pandiontx.com/news-releases/news-release-details/pandion-therapeutics-announces-positive-top-line-phase-1a


$PRVB (+7.79%) - Provention Bio Announces U.S. FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals

http://investors.proventionbio.com/2021-01-04-Provention-Bio-Announces-U-S-FDA-Filing-of-a-Biologics-License-Application-BLA-and-Priority-Review-for-Teplizumab-for-the-Delay-or-Prevention-of-Clinical-Type-1-Diabetes-in-At-risk-Individuals



0 comments

*Disclaimer: Information provided on bpiq.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Movers™ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.

SITE